Clinical Trial Update: Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial of Letetresgene Autoleucel (engineered T cells) in NY-ESO-1 positive advanced myxoid/round cell liposarcoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myxoid Liposarcoma
• Neoplasms
• Round Cell Liposarcoma

Drugs mentioned

• Letetresgene Autoleucel (letetresgene autoleucel)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2022-11-28